BR112013028652A8 - Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos - Google Patents

Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos

Info

Publication number
BR112013028652A8
BR112013028652A8 BR112013028652A BR112013028652A BR112013028652A8 BR 112013028652 A8 BR112013028652 A8 BR 112013028652A8 BR 112013028652 A BR112013028652 A BR 112013028652A BR 112013028652 A BR112013028652 A BR 112013028652A BR 112013028652 A8 BR112013028652 A8 BR 112013028652A8
Authority
BR
Brazil
Prior art keywords
methods
growth factor
equine
neuronal growth
antibodies
Prior art date
Application number
BR112013028652A
Other languages
English (en)
Other versions
BR112013028652A2 (pt
Inventor
Gearing David
Original Assignee
Nvip Pty Ltd
Nexvet Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nvip Pty Ltd, Nexvet Australia Pty Ltd filed Critical Nvip Pty Ltd
Publication of BR112013028652A2 publication Critical patent/BR112013028652A2/pt
Publication of BR112013028652A8 publication Critical patent/BR112013028652A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ANTICORPOS ANTI-FATOR DE CRESCIMENTO NEURONAL E MÉTODOS PARA PREPARAÇÃO E UTILIZAÇÃO DOS MESMOS É fornecido um método de preparação de um anticorpo adequado para uso em um equino. Também são fornecidos anticorpos "equinizados" que se ligam especificamente ao fator de crescimento neuronal equino (NGF) e neutralizam a habilidade de NGF equino para se ligar ao receptor de NGF equino p75 TrkA. A invenção se estende aos ácidos nucléicos que o codificam e aos métodos de tratamento de dor e artrite em um equino usando os referidos anticorpos e/ou ácidos nucléicos.
BR112013028652A 2011-05-06 2012-05-08 Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos BR112013028652A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161483491P 2011-05-06 2011-05-06
US201161531439P 2011-09-06 2011-09-06
PCT/GB2012/051004 WO2012153123A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Publications (2)

Publication Number Publication Date
BR112013028652A2 BR112013028652A2 (pt) 2016-11-29
BR112013028652A8 true BR112013028652A8 (pt) 2017-12-26

Family

ID=46168541

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028652A BR112013028652A8 (pt) 2011-05-06 2012-05-08 Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos

Country Status (14)

Country Link
US (2) US20140170136A1 (pt)
EP (2) EP3502136A1 (pt)
JP (2) JP6181043B2 (pt)
KR (1) KR101833465B1 (pt)
CN (1) CN103764677A (pt)
AU (1) AU2012252153B2 (pt)
BR (1) BR112013028652A8 (pt)
CA (1) CA2834983C (pt)
ES (1) ES2704007T3 (pt)
GB (1) GB2504888B (pt)
MY (1) MY160884A (pt)
RU (1) RU2640252C2 (pt)
SG (2) SG194795A1 (pt)
WO (1) WO2012153123A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
KR101833465B1 (ko) * 2011-05-06 2018-02-28 넥스베트 오스트레일리아 피티와이 리미티드 항신경 성장 인자 항체 및 그의 제조방법과 이용방법
US10023636B2 (en) 2013-12-20 2018-07-17 Intervet Inc. Caninized murine antibodies to human PD-1
BR112017006203A2 (pt) 2014-09-30 2018-05-02 Intervet International B.V. anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
TWI706959B (zh) * 2015-05-22 2020-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＮＧＦ抗體Ｆａｂ片段
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP2020531002A (ja) * 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
US10799289B2 (en) 2018-10-15 2020-10-13 Avent, Inc. Compositions, systems, kits, and methods for neural ablation
WO2022087153A1 (en) * 2020-10-22 2022-04-28 Scout Bio, Inc. Method of suppressing immune response to vector-delivered therapeutic protein
KR20240006586A (ko) 2021-05-12 2024-01-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
CN118475612A (zh) 2021-08-31 2024-08-09 斯科特生物公司 抗原结合分子及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
AU632843B2 (en) * 1989-08-10 1993-01-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
AU2005243247B2 (en) * 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
CA2791560A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics Inc. Monoclonal antibodies directed to cd20
BR112012022342A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
RS63063B1 (sr) * 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antitela i njihova upotreba
KR101833465B1 (ko) * 2011-05-06 2018-02-28 넥스베트 오스트레일리아 피티와이 리미티드 항신경 성장 인자 항체 및 그의 제조방법과 이용방법

Also Published As

Publication number Publication date
JP6181043B2 (ja) 2017-08-16
US20190276525A1 (en) 2019-09-12
JP6526089B2 (ja) 2019-06-05
RU2640252C2 (ru) 2017-12-27
GB2504888B (en) 2016-02-03
US20140170136A1 (en) 2014-06-19
KR20140041532A (ko) 2014-04-04
BR112013028652A2 (pt) 2016-11-29
CA2834983A1 (en) 2012-11-15
EP2705056B1 (en) 2018-11-14
JP2014519318A (ja) 2014-08-14
CA2834983C (en) 2020-11-17
AU2012252153A8 (en) 2013-12-19
RU2013154307A (ru) 2015-06-20
SG194795A1 (en) 2013-12-30
NZ617448A (en) 2015-01-30
WO2012153123A1 (en) 2012-11-15
EP3502136A1 (en) 2019-06-26
GB201320050D0 (en) 2013-12-25
MY160884A (en) 2017-03-31
AU2012252153B2 (en) 2016-07-07
CN103764677A (zh) 2014-04-30
JP2017123870A (ja) 2017-07-20
GB2504888A (en) 2014-02-12
SG10201500957QA (en) 2015-04-29
KR101833465B1 (ko) 2018-02-28
AU2012252153A1 (en) 2013-11-14
EP2705056A1 (en) 2014-03-12
ES2704007T3 (es) 2019-03-13

Similar Documents

Publication Publication Date Title
BR112013028652A8 (pt) Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos
BR112013028654A2 (pt) anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos
BR112013028655A2 (pt) anticorpos anti-fator de crescimento neuronal e método para preparação e utilização dos mesmos
BR112018014585A2 (pt) receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
BRPI1014522B8 (pt) anticorpo anti-actriib ou fragmento funcional, processo de produção dos mesmos, composição farmacêutica e usos
BR112014011331A2 (pt) anticorpos específicos para trop-2 e seus usos
BR112016009797A2 (pt) anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
CL2015002526A1 (es) Anticuerpos anti-ox40 y métodos de uso de los mismos.(divisional de 545-13).
CL2015003090A1 (es) Proteínas de unión específicas y sus usos.
BR112018000604A8 (pt) Moléculas de anticorpo que ligam cd45
BR112015010722A2 (pt) Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
MX2011000768A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
BR112014020826A8 (pt) Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
WO2015108998A3 (en) Cartilage targeting agents and their use
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
EA201592154A1 (ru) Способ улучшения латентной гидравлической и/или пуццолановой активности материалов
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
EA201401065A1 (ru) Ang2-связывающие молекулы
BR112013021134A8 (pt) Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico
CL2008002083A1 (es) Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
CL2013002743A1 (es) Cristal de anticuerpo de igg anti-esclerostina; metodo de produccion; composicion que lo comprende; y su uso para tratar desordenes oseos.
BR112015010817A2 (pt) anticorpos anti-hemaglutinina, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: NVIP PTY LTD (AU)

B25A Requested transfer of rights approved

Owner name: NEXVET AUSTRALIA PTY LTD (AU)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements